Niagen Bioscience Reports 33% Revenue Growth to $33.986 Million in Latest Quarter

Niagen Bioscience, Inc. reported significant financial growth in its latest quarterly filing, with net sales reaching $33.986 million for the three months ended September 30, 2025, a 33% increase from $25.580 million in the same period last year. For the nine months ending September 30, 2025, the company recorded net sales of $95.584 million, up 36% from $70.472 million in 2024. The increase in revenue was primarily driven by strong performance in the consumer products segment, particularly the Tru Niagen® product line, which saw sales rise by $7.9 million and $16.1 million for the three and nine months, respectively. The company also reported a net income of $4.578 million for the third quarter, compared to $1.878 million in the prior year, and a net income of $13.250 million for the nine-month period, up from $1.371 million.

The company’s operational metrics indicate a positive trend, with gross profit for the third quarter increasing to $21.928 million, a 35% rise from $16.240 million in 2024. The gross profit margin improved due to enhanced operational efficiency and a favorable product mix. Operating expenses also increased, with total operating expenses for the third quarter rising to $17.692 million from $14.638 million in the previous year, reflecting increased investments in sales and marketing as well as research and development. Notably, the company’s employee headcount has also grown, contributing to higher general and administrative expenses, which totaled $7.129 million for the third quarter, up from $6.304 million in 2024.

Niagen Bioscience has made strategic moves to bolster its market position, including the launch of its Niagen Plus product line aimed at healthcare practitioners and clinics. The company has also entered into a significant supply agreement with W. R. Grace & Co. for Nicotinamide-beta-Riboside Chloride, which is expected to enhance its ingredient supply chain through 2029. This agreement includes a commitment to purchase approximately $33.6 million in inventory over the next year, reflecting the company's focus on securing its supply of key ingredients.

The company reported a total cash and cash equivalents balance of $64.290 million as of September 30, 2025, an increase from $44.660 million at the end of 2024. This liquidity position is expected to support the company’s operational needs and strategic initiatives over the next twelve months. Management has indicated that while current cash flows are sufficient to meet obligations, they may seek additional capital to fund long-term growth strategies. The company remains optimistic about its future, citing ongoing demand for its products and the potential for further market expansion.